![Harald Poth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Harald Poth
Président chez
Phenex Pharmaceuticals AG
Profil
Harald Poth is currently the Chairman-Supervisory Board at Phenex Pharmaceuticals AG, Director at Acousia Therapeutics GmbH, and Senior Investment Manager at LBBW Venture Capital GmbH.
He holds a doctorate degree from the University of Hohenheim.
Postes actifs de Harald Poth
| Sociétés | Poste | Début |
|---|---|---|
LBBW Venture Capital GmbH
 LBBW Venture Capital GmbH Investment ManagersFinance LBBW Venture Capital invests in companies located in DACH region. The firm targets companies operating in the fields of disruptive information technology, life sciences, software, digital formation and fintech. It provides financing for seed and early stage capital requirements with an investment size up to EUR 3 million. | Private Equity Investor | - |
Phenex Pharmaceuticals AG
 Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Specializes in identification and analysis of selective drug candidates for nuclear receptors using its SNuRM technology | Président | - |
Acousia Therapeutics GmbH
 Acousia Therapeutics GmbH BiotechnologyHealth Technology Develops drugs for local application | Directeur/Membre du Conseil | - |
Formation de Harald Poth
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
20
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
LBBW Venture Capital GmbH
LBBW Venture Capital GmbH Investment ManagersFinance LBBW Venture Capital invests in companies located in DACH region. The firm targets companies operating in the fields of disruptive information technology, life sciences, software, digital formation and fintech. It provides financing for seed and early stage capital requirements with an investment size up to EUR 3 million. | Finance |
University of Hohenheim
 University of Hohenheim Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Phenex Pharmaceuticals AG
Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Specializes in identification and analysis of selective drug candidates for nuclear receptors using its SNuRM technology | Health Technology |
Acousia Therapeutics GmbH
Acousia Therapeutics GmbH BiotechnologyHealth Technology Develops drugs for local application | Health Technology |
